Synapse - Lorenzo Falchi

Results (136)

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Research Letter

Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
Cancer Cell (2022)

Fulltext@MSK | Save

Subcutaneous epcoritamab in combination with rituximab and lenalidomide in relapsed or refractory follicular lymphoma: Preliminary phase 1/2 results

Meeting Abstract

Linton, K. M.; Wahlin, B.; Leppä, S.; Morschhauser, F.; Elliott, B.; Liu, T.; Stirner, M. C.; Abbas, A.; Falchi, L.
British Journal of Haematology (2022)

Fulltext@MSK | Save

Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience

Journal Article

Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Brentuximab vedotin and bendamustine produce long-term clinical benefit in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter real-life experience

Journal Article

Moretti, M.; Liberati, A. M.; Rigacci, L.; Puccini, B.; Pulsoni, A.; Gini, G.; Galieni, P.; Fabbri, A.; Cantonetti, M.; Pavone, V.; more...
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Journal Article

Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
Blood Cancer Journal (2022)

Fulltext@MSK | Save

Global cytopathology-hematopathology practice trends

Journal Article

Zadeh, S. L.; Balassanian, R.; Cheung, M. C.; Falchi, L.; Hasserjian, R.; Lin, O.; Long, S. R.; Ly, A.; Menke, J. R.; Mou, E.; more...
American Journal of Clinical Pathology (2022)

Fulltext@MSK | Save

Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade

Meeting Abstract

Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
Blood (2021)

Fulltext@MSK | Save

Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
Blood (2021)

Fulltext@MSK | Save

A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach

Meeting Abstract

Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
Blood (2021)

Fulltext@MSK | Save

Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience

Meeting Abstract

Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
Blood (2021)

Fulltext@MSK | Save